Australia's most trusted
source of pharma news
Thursday, 07 November 2024
Posted 7 November 2024 AM
Humira biosimilar market leader, Sandoz, is looking to retain its position with a new citrate-free high-concentration formulation (HCF) of Hyrimoz on the cusp of PBS listing.
Hyrimoz was the highest earning biosimilar of AbbVie's blockbuster Humira in the 2022-23 financial year, earning $16.1 million, according to the latest PBS Expenditure and Prescriptions report.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.